Advances in the treatment of Parkinson's disease

Drugs of Today

Volumn 34, Issue 2, 1998, Pages 95-105

  Pahwa, Rajesh ^a   Koller, William C ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; LEVODOPA; PERGOLIDE MESILATE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE;

DOPAMINE METABOLISM; DOSE RESPONSE; DRUG EFFECT; DRUG METABOLISM; DYSKINESIA; GASTROINTESTINAL TOXICITY; HALLUCINATION; HUMAN; HYPOTENSION; NEUROPROTECTION; PARKINSON DISEASE; REVIEW; SUSTAINED RELEASE PREPARATION; TREATMENT PLANNING; VERTIGO;

EID: 0031966832     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1998.34.2.485183     Document Type: Review

References (112)

1. Calne, D.B. Treatment of Parkinson's disease. New Engl J Med 1993, 329: 1021-7.
2. Koller, W.C., Hubble, J.P. Levodopa therapy in Parkinson's disease. Neurology 1990, 40 (Suppl. 3): 40-7.
3. Marsden, C.D., Parkes, J.D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977, i: 345-9.
4. Poewe, W.H., Lees, A.J., Stern, G.M. Low-dose L-dopa therapy in Parkinson's disease: A 6-year follow-up study. Neurology 1986, 36: 1528-30.
5. Bloch, G., Liss, G., Reiner, S. et al. Comparison of immediate-release and controlled-release carbidopa-levodopa in Parkinson's disease. Eur Neural 1997, 37: 23-7.
6. Quinn, N., Critchley, P., Marsden, C.D. Young onset Parkinson's disease. Mov Disord 1987, 2: 73-91.
7. Golbe, L.I. Young-onset Parkinson's disease: A clinical review. Neurology 1991, 41: 168-73.
8. Fahr, S., Bressman, S.B. Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984, 11: 200-6.
9. Melamed, E. Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. Arch Neurol 1986, 43: 402-5.
10. Markham, C.H., Diamond, S.G. Modification of Parkinson's disease by long-term levodopa treatment. Arch Neurol 1986, 43: 405-7.
11. Sage, J.I., Mark, M.H. The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease. Neurology 1992, 42 (Suppl. 1): 23-8.
12. Jenner, P., Boyce, S., Marsden, C.D. Effect of repeated L-dopa administration on striatal dopamine receptor function in the rat. In: Recent Developments in Parkinson's Disease. Fahn, S., Marsden, C.D., Jenner, P. et al. (Eds.). Raven Press: New York 1986, 189-203.
13. Juncos, J.O., Engber, T.M., Raisman, R. et al. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 1989, 25: 473-8.
14. Mouradian, M.M., Juncos, J.L., Fabbrinis, G. et al. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II. Ann Neurol 1988, 24: 372-8.
15. Mouradian, M.M., Chase, T.N. Improved dopaminergic therapy of Parkinson's disease. In: Movement Disorders 3. Marsden, C.D., Fahn, S. (Eds.). Butterworth Heinemann: Oxford 1994, 180-99.
16. Calne, D.B., Duvoisin, R.C., Killer, W.C. Individualizing therapy in patients with disabling Parkinson's disease symptoms. Neurology 1994, 44 (Suppl. 1): 8-11.
17. Rinne, U.K. Controlled-release levodopa superior to standard levodopa in the treatment of early Parkinson's disease. Mov Disord 1990, 5 (Suppl. 1): 52.
18. DuPont, E., Anderson, A., Bors, J. et al. Sustained-release Madopar HBS® compared to standard Madopar® in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 1996, 93: 14-20.
19. Rajput, A.M., Stern, W., Laverty, W.H. Chronic low-dose levodopa therapy in Parkinson's disease: An argument for delaying levodopa therapy. Neurology 1984, 34: 991-6.
20. Poewe, W.H., Lees, A.J., Stern, G.M. Low-dose L-dopa therapy in Parkinson's disease. A six-year follow-up study. Neurology 1896, 36: 1528-30.
21. Rosen, J.A. The effect of a monoamine oxidase inhibitor on the bradykinesia of human parkinsonism. In: Progress in Neurogenetics. Congress Series No. 175. Barbeau, A. Brunette, J.R. (Eds.). Excerpta Medica: Amsterdam 1969, 346-51.
22. Golbe, L., Lieberman, A., Muenter, M. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988, 2: 45-55.
23. Tetrud, J.W., Langston, J.W. The effect of deprenyl (selegiline) in the natural history of Parkinson's disease. Science 1989, 245: 519-22.
24. Teravainen, H. Selegiline in Parkinson's disease. Acta Neurol Scand 1990, 81: 333-6.
25. Parkinson's Study Group. DATATOP: A multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989, 46: 1052-60.
26. Olanow, C.W., Calne, D. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanism? Neurology 1991, 42 (Suppl. 6): 13-26.
27. Parkinson's Study Group. Impact of deprenyl and -tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996, 39: 29-36.
28. Olanow, C.W., Hauser, R.A., Gauger, L. et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995, 38: 771-7.
29. Guldberg, H.C., Marsen, C.D. Catechol-O-methyltransferase: Pharmacological aspects and physiological role. Pharmacol Rev 1975, 27: 135-206.
30. Schultz, E. Catechol-O-methyltransferase and aromatic L-amino decarboxylase activities in human gastrointestinal tissues. Life Sci 1991, 49: 721-5.
31. Mannistō, P.T., Ulmanen, I., Lundström, K. et al. Characteristics of catechol-methyltransferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 1992, 120: 1-29.
32. Nut, J.G., Fellman, J.H. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984, 7: 35.
33. Da Prada, M., Keller, H.H., Pieri, L., Kettler, R., Haefely, W.E. The pharmacology of Parkinson's disease: Basic aspects and recent advances. Experientia 1984, 40: 1165-304.
34. Kuruma, I., Bartholini, G., Tissot, R., Pletscher, A. The metabolism of L-3-O-methyldopa, a precursor of dopa in man. Clin Pharmacol Ther 1971, 12: 678-82.
35. Nut, J.G., Woodward, W.R., Grancher, S.T., Merrick, D. 3-O Methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 1987, 21: 584-8.
36. Muenter, M.D., Dinapoli, R.P., Sharpless, N.S., Tyce, G.M. 3-O-Methyldopa, L-dopa and trihexyphenidyl in the treatment of Parkinson's disease. Mayo Clin Proc 1973, 48: 173-83.
37. Ball, P., Knupper, R., Bruer, H. Purification and properties of catechol-O-methyltransferase of human liver. Eur J Biochem 1971, 21: 517.
38. Hardebo, J.E., Owman, C. Barrier mechanisms for neurotransmitter monoamines and their precursors at the blood-brain interface. Ann Neurol 1980, 8: 1-11.
39. Wade, L.A., Katzman, R. 3-O-Methyldopa uptake and inhibition of L-dopa at the blood brain barrier. Life Sci 1975, 17: 131-6.
40. Reches, A., Fahn, S. 3-O-Methyldopa blocks dopa metabolism in rat corpus stratum. Ann Neurol 1982, 12: 267-71.
41. Cedarbaum, J.M., Kutt, H., McDowell, F.H. Clinical significance of the relationship between O-methyldopa levels and levodopa intake. Neurology 1988, 38: 533-6.
42. Fabbrini, G., Juncos, J.L., Mouradian, M.M., Serrati, C., Chase, T.N. 3-O-Methyldopa and motor fluctuations in Parkinson's disease. Neurology 1987, 37: 856-9.
43. Mannistō, P.T., Tuomainen, P., Tuominen, R.K. Different in vivo properties of three new inhibitors of catechol-O-methyltransferase in the rat. Br J Pharmacol 1992, 105: 569-74.
44. Nissinen, E., Linden, I., Schultz, E., Pohto, P. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Arch Pharmacol 1992, 346: 262-6.
45. Kerānen, T., Gordin, A., Karlsson, M. et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 1994, 46: 151-7.
46. Keranen, T., Gordin, A., Harjola, V. et al. The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993, 16: 145-56.
47. Kaakkola, S., Teravainen, H., Ahtila, S., Rita, H., Gordin, A. Effect of entacapone, a COMT inhibitor, on clinical disability and L-dopa metabolism in parkinsonian patients. Neurology 1994, 44: 77-80.
48. Nut, J.G., Woodward, W.R., Beckner, R.M. et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994, 44: 913-9.
49. Parkinson Study Group. The COMT inhibitor entacapone improves parkinsonian features in fluctuating patients. Mov Disord 1996, 11 (Suppl. 1): 268.
50. Spencer, C.M., Benfield, P. Tolcapone. CNS drugs 1996, 475-81.
51. Limousin, P., Pollak, P., Gervason-Tournier, C., Hommel, M., Pierret, J.E. Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease. Lancet 1993, 341: 1605.
52. Pollack, P., Limousin, P., Gervason, C., Perret, J. Prolongation of levodopa-induced "on" motor periods by Ro 40-7592, a catechol-O-methyltransferase inhibitor in Parkinson's disease. Ann Neurol 1993, 32: 316.
53. Roberts, J.W., Cora-Locatelli, G., Bravi, D. et al. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1993, 43: 2685-8.
54. Kurth, M.C., Adler, C.H., St. Hilaire, M. et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter. double-blind, randomized, placebo controlled trial. Neurology 1997, 48: 81-7.
55. Dorflinger, E.E., Nutley, N.J., Rajput, A. et al. Multicenter evaluation of tolcapone (Tasmar) when given together with levodopa to Parkinson's disease patients who exhibit end-of-dose wearing-off. Neurology 1996, 46 (Suppl. 2): Abst A474.
56. Waters, C.H., Kurth, M.C., Shulman, L. et al. Evaluation of the efficacy and safety of tolcapone (Tasmar) in Parkinson's disease patients with a stable response to levodopa. Neurology 1996, 46 (Suppl. 2): Abst A160.
57. Guttman, M. Dopamine receptors in Parkinson's disease. Neural Clin 1992, 10: 377-86.
58. 2 dopamine receptor in the intermediate lobe of the rat pituitary gland: A review. Neuroendocrinology 1982, 35: 217-24.
59. Lieberman, A.N., Gopinathan, G., Neophytides, A. et al. Management of levodopa failures: The use of dopamine agonists. Clin Neuropharmacol 1986, 9 (Suppl. 2): S9-21.
60. Rubin, A., Lemberger, L., Dhahir, P. Physiologic disposition of pergolide. Clin Pharmacol Ther 1981, 30: 258-65.
61. Goetz, C.G., Diederich, N.J. Dopaminergic agonists in the treatment of Parkinson's disease. Neurol Clin 1992, 10: 527-40.
62. Rinne, U.K. Dopamine agonists as primary treatment in Parkinson's disease. Adv Neurol 1986, 45: 519-23.
63. Mizuno, Y., Kondo, Y., Narabayashi, H. Pergolide in the treatment of Parkinson's disease. Neurology 1995, 45 (Suppl. 3): S13-21.
64. Caraceni, T., Giovanni, P., Parati, E. et al. Bromocriptine and lisuride in Parkinson's disease. Adv Neurol 1984, 40: 531-5.
65. Goetz, C.G., Tanner, C.M., Glantz, R.H., Klawans, H.L. Chronic agonist therapy for Parkinson's disease: A five-year study of bromocriptine and pergolide. Neurology 1985, 35: 749-51.
66. Hoehn, M.M., Elton, R.L. Low dosages of bromocriptine added to levodopa in Parkinson's disease. Neurology 1985, 35: 199-206.
67. Nut, J.G., Hammerstad, J.P., Gancher, S.T. Therapy: Dopamine agonists. In: Parkinson's Disease, 100 Maxims. Mosby Year Book: St. Louis 1992, 93-101.
68. Lieberman, A.N., Leibowitz, M., Neophytides, A. et al. Pergolide and lisuride for Parkinson's disease. Lancet 1979, 2: 1129-30.
69. Klawans, H.L., Tanner, C.M., Goetz, C.G. et al. Pergolide mesylate therapy in Parkinson's disease: Report of a 3-month trial in 20 patients. Neurology 1981, 31: 133.
70. Lang, A.K., Quinn, N., Brincat, S., Marsden, C.D., Parkes, J.D. Pergolide in late-stage Parkinson's disease. Ann Neurol 1982, 12: 243-7.
71. Tanner, C.M., Goetz, C.G., Glantz, R.H., Glatt, S.L., Klawans, H.L. Pergolide mesylate and idiopathic Parkinson's disease. Neurology 1982, 32: 1175-90.
72. Olanow, C.W., Alberts, M.J. Double-blind controlled study of pergolide mesylate in the treatment of Parkinson's disease. Clin Neuropharmacol 1987, 10: 178-85.
73. Jankovic, J., Orman, J. Parallel double-blind study of pergolide in Parkinson's disease. Adv Neurol 1986, 45: 551-4.
74. Lieberman, A.N., Goldstein, M., Neophytides, A. et al. The use of pergolide, a potent dopamine agonist in Parkinson's disease. Clin Pharmacol Ther 1982, 32: 70-5.
75. Shoulson, I., Miller, C., Kurlan, R., Levy, R., Macik, B. Parkinsonism and on-off fluctuations: Long-term effects of pergolide therapy. Ann Neurol 1982, 12: 97.
76. Goetz, C.G., Tanner, C.M., Glantz, R., Klawans, H.L. Pergolide in Parkinson's disease. Arch Neurol 1983, 40: 785-7.
77. Lieberman, A.N., Goldstein, M., Leibowitz, M., Gopinathan, G., Neophytides, A. Long-term treatment with pergolide: Decreased efficacy with time. Neurology 1984, 34: 223-6.
78. Kurlan, R., Miller, C., Levy, R. et al. Long-term experience with pergolide therapy of advanced parkinsonism. Neurology 1985, 35: 738-42.
79. Jankovic, J. Long-term study of pergolide in Parkinson's disease. Neurology 1985, 35: 296-9.
80. Ahlskog, J.E., Muenter, M.D. Pergolide: Long-term use in parkinson's disease. Mayo Clin Proc 1988, 63: 979-87.
81. Lieberman, A.N., Goldstein, M., Leibowitz, M. et al. Treatment of advanced Parkinson's disease with pergolide. Neurology 1981, 31: 675-82.
82. Leibowitz, M., Lieberman, A., Goldstein, M. et al. Cardiac effects of pergolide. Clin Pharmacol Ther 1981, 30: 718-23.
83. Schingnitz, G., Mierau, J. Post synaptic dopamine agonistic effects of the autoreceptor agonist pramipexole. Biol Psychiatry 1991, 29: Abst 609-S.
84. 2-receptor agonist. Eur J Pharmacol 1992, 215: 161-70.
85. Wright, C.E., Sisson, T.L., Ichhpurani, A.K., Peters, G.R. Pramipexole steady-state pharmacokinetics in healthy volunteers. Clin Neuropharmacol, in press.
86. Hubble, J.P., Killer, W.C., Cutler, N.R. et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995, 18: 338-47.
87. Molho, E.S., Factor, S.A., Weiner, W.J. et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm 1995, 45 (Suppl): 225-30.
88. Andreotti, A.C., Pianezzola, E., Persiani, S., Pacciarini, M.A., Strolin-Benedetti, M., Pontiroli, A.K. Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin lowering drug, after administration of increasing oral doses in healthy male volunteers. J Clin Endocrinol Metab 1995, 80: 841-5.
89. Jori, M.C., Franceschi, M., Giusti, M.C. et al. Clinical experience with cabergoline, a new ergoline derivative in the treatment of Parkinson's disease. Adv Neurol 1990, 53: 539-43.
90. Persiani, S., Rocchetti, M., Pacciarini, M.A., Holt, B., Toon, S., Strolin-Benedetti, M. The effect of food on cabergoline pharmacokinet- ics and tolerability in healthy volunteers. Biopharm Drug Dispos 1996, 17: 443-55.
91. Lera, G., Vaamonde, J., Muruzabal, J., Obeso, J.A. Cabergoline: A long-acting dopamine agonist in Parkinson's disease. Ann Neurol 1990, 28: 593-4.
92. Obeso, J.A., Lera, G., Vaamonde, J., Martínez-Lage, J.M. Cabergoline for the treatment of motor complications of Parkinson's disease. Neurology 1991, 41 (Suppl. 1): Abst 172.
93. Ahlskog, J.E., Muenter, M.D., Maraganore, D.M. et al. Fluctuating Parkinson's disease: Treatment with long-acting dopamine agonist Cabergoline. Arch Neurol 1994, 51: 1236-41.
94. Hutton, J.T., Koller, W.C., Ahlskog, J.E., Pahwa, R. et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996, 46: 1062-5.
95. Boothman, B.R., Spokes, E.G. Pharmacokinetic data for ropinirole. Lancet 1990, 336: 814.
96. 2 agonist. Pharmacol Biochem Behav 1991, 38: 147-54.
97. Rascol, O., Lees, A.J., Senard, J.M., Pirtosek, Z., Montastruc, J.L., Fuell, D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996, 19: 234-45.
98. 2 agonist, in the treatment of motor fluctuations of L-dopa-treated parkinsonian patients. Adv Neurol 1996, 69: 531-4.
99. Brooks, D.J., Torjanski, N., Burn, D.J. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm 1995, 45 (Suppl.): 231-8.
100. Neumeyer, J.L., Lal, S., Baldessarini, R.J. Historical highlights of the chemistry, pharmacology, and early clinical uses of apomorphine. In: Apomorphine and Other Dopaminomimetics. Vol. 1: Basic Pharmacology. Gessa, G.L., Corsini, G.U. (Eds.). Raven Press: New York 1981, 1-17.
101. Schwab, R.S., Amador, L.V., Lettvin, J.Y. Apomorphine in Parkinson's disease. Transm Am Neurol Assoc 1951, 76: 251-3.
102. Duby, S.E., Cotzias, G.C., Papavasilious, P.S., Lawrence, W.H. Injected apomorphine and orally administered levodopa in parkinsonism. Neurology 1972, 27: 474-80.
103. Cotzias, G.C., Papavasilious, P.S., Fehling, G., Kaufman, B., Mena, I. Similarities between neurologic effects of L-dopa and of apomorphine. New Engl J Med 1970, 282: 31-3.
104. Cotzias, G.C., Papavasilious, P.S., Tolosa, E.S., Mendez, J., Bell-Midura, M. Treatment of Parkinson's disease with apomorphine. New Engl J Med 1976, 294: 567-72.
105. Parkes, J.D. Domperidone and Parkinson's disease. Clin Neuropharmacol 1986, 9: 511-2.
106. Corsini, G.U., Gessa, G.L., Del Zompo, M., Mangoni, A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet 1979, i: 954-6.
107. Gancher, S.T., Nut, J.G., Woodward, W.R. Absorption of apomorphine by various routes in parkinsonism. Mov Disord 1991, 6: 212-6.
108. Baldessarini, R.J., Arano, G.W., Kula, N.S., Campbell, A., Harding, M. Preclinical studies of the pharmacology of apomorphines. In: Apomorphine and Other Dopaminomimetics. Vol. 1: Basic Pharmacology. Gessa, G.L., Corsini, G.U. (Eds.). Raven Press: New York 1981, 219-28.
109. Gancher, S.T., Woodward, W.R., Boucher, B., Nut, J.G. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989, 26: 232-8.
110. Poewe, W., Kleedorfer, B., Gerstenbrand, F., Oerterl, W. Subcutaneous apomorphine in Parkinson's disease. Lancet 1988, i: 943.
111. Stibe, C.M., Kempster, P.A., Lees, A.J., Stern, G.M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988, i: 403-6.
112. Frankel, J.P., Lees, A.J., Kempster, P.A., Stern, G.M. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990, 53: 96-101.